Avicanna Announces Medical Cannabis Real World Evidence Results and Publication

Core Insights - The publication reports significant improvements in pain-related outcomes, mental health measures, and quality of life among chronic pain patients using physician-authorized medical cannabis, as detailed in a study published in the Canadian Journal of Pain [1][6]. Study Overview - The study is a prospective, observational analysis evaluating patient-reported outcomes among chronic pain patients receiving medical cannabis under healthcare provider supervision, supported by multiple clinicians and medical institutions across Canada [2][3]. - The study was led by Dr. Hance Clarke at the University Health Network (UHN) and utilized the MyMedi.ca platform for data collection and patient support [1][8]. Study Results - Statistically significant improvements were observed in pain interference and pain intensity, as well as in anxiety, depressive symptoms, and overall quality of life over a 24-week follow-up period [5]. - Although the magnitude of change did not meet established minimal clinically important difference thresholds, the directional improvements align with existing literature on medical cannabis [5]. Scientific and Clinical Significance - The study represents a milestone for Avicanna, emphasizing the importance of high-quality, prospective real-world data in complementing randomized clinical trials and informing clinical practice [7]. - As regulatory frameworks evolve, physician-supervised models and rigorous data generation will be crucial for advancing cannabinoid-based medicines [7]. Ongoing Research and Development - The MCRWE study is ongoing, with continued patient recruitment across seven Canadian provinces, focusing on various outcomes associated with medical cannabis use [9]. - Avicanna is involved in providing the necessary infrastructure for large-scale real-world evidence research, ensuring that clinical decision-making and patient care remain unaffected [8]. Company Background - Avicanna is a biopharmaceutical company dedicated to the development and commercialization of cannabinoid-based products for medical and pharmaceutical markets, with over thirty proprietary products [11]. - The company has established a scientific platform that includes R&D and clinical development, supporting its commercial operations [11].